Your browser doesn't support javascript.
loading
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Bischoff, Joachim; Barinoff, Jana; Mundhenke, Christoph; Bauerschlag, Dirk O; Costa, Serban-Dan; Herr, Daniel; Lübbe, Kristina; Marmé, Frederik; Maass, Nicolai; von Minckwitz, Gunter; Grischke, Eva-Maria; Müller, Volkmar; Schmidt, Marcus; Gerber, Bernd; Kümmel, Sherko; Schumacher, Claudia; Krabisch, Petra; Seiler, Sabine; Thill, Marc; Nekljudova, Valentina; Loibl, Sibylle.
Afiliación
  • Bischoff J; Women's Hospital, Städtisches Klinikum Dessau.
  • Barinoff J; Women's Hospital, Agaplesion Markus-Krankenhaus, Frankfurt am Main.
  • Mundhenke C; Gynaecological Hospital, Charité Universitätsmedizin Berlin.
  • Bauerschlag DO; University Women's Hospital Kiel, UK-SH, Kiel.
  • Costa SD; University Women's Hospital Kiel, UK-SH, Kiel.
  • Herr D; University Women's Hospital Magdeburg, Otto-von Guericke-Universität, Magdeburg.
  • Lübbe K; University Women's Hospital Würzburg.
  • Marmé F; Breast Center, Diakovere Henriettenstiftung, Hannover.
  • Maass N; National Center for Tumor Diseases, University Hospital Heidelberg.
  • von Minckwitz G; University Women's Hospital Kiel, UK-SH, Kiel.
  • Grischke EM; German Breast Group, Neu-Isenburg.
  • Müller V; Women's Hospital, University Hospital Tübingen.
  • Schmidt M; Women's Hospital, UKE University Hospital Hamburg-Eppendorf KMTZ, Hamburg.
  • Gerber B; Women's Hospital, University Medical Center Mainz.
  • Kümmel S; Women's Hospital, University Hospital Rostock.
  • Schumacher C; Women's Hospital, Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen.
  • Krabisch P; Breast Center, St. Elisabeth Krankenhaus Hohenlind, Cologne.
  • Seiler S; Women's Hospital, Klinikum Chemnitz, Germany.
  • Thill M; German Breast Group, Neu-Isenburg.
  • Nekljudova V; Women's Hospital, Agaplesion Markus-Krankenhaus, Frankfurt am Main.
  • Loibl S; German Breast Group, Neu-Isenburg.
Anticancer Drugs ; 30(4): 394-401, 2019 04.
Article en En | MEDLINE | ID: mdl-30875348
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor ErbB-2 Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Anticancer Drugs Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor ErbB-2 Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Anticancer Drugs Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article